Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brigette Roberts
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Beta
- 1.33
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -7.94
Financials
Net Income
$-27.74MEBITDA
$-13.14MFree Cash Flow
$-9.91MEPS (diluted)
$-2.31Shares Outstanding (diluted)
12.00M+11040.7%Operating Expenses
$14.87MCash & Debt
$105.24MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-83.98M | $-336.00 |
| 2024 | $0.00 | $-56.83M | $-262.00 |
| 2023 | $0.00 | $-31.39M | $-168.00 |
| 2022 | $0.00 | $-51.66M | $-308.00 |
| 2021 | $0.00 | $-89.94M | $-606.00 |
| 2020 | $0.00 | $-76.85M | $-526.00 |
| 2019 | $0.00 | $-36.98M | $-386.00 |
| 2018 | $0.00 | $-12.48M | $-116.00 |
| 2017 | $0.00 | $-12.23M | $-114.00 |
Valuation
QNCXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·44d ago·Positive
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R.
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Quince Therapeutics to Participate in September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
View source ↗
Earnings
Typical surprise -21.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-12.31 vs $-28.02beat
- Tue, May 12$75.60 vs $-26.00beat
- Mon, Apr 6$-3.50 vs $-3.59beat
- Wed, Nov 12$-50.00 vs $-40.00miss
- Mon, Aug 11$-68.00 vs $-56.00miss
- Tue, May 13$-68.00 vs $-48.00miss
Estimates and results for QNCX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in QNCX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
